FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028763729> ?p ?o ?g. }

• W2028763729 endingPage "343" @default.
• W2028763729 startingPage "338" @default.
• W2028763729 abstract "Carcinoembryonic antigen glypican-3 (GPC3) is expressed by >40% of ovarian clear cell carcinoma (CCC) and is a promising immunotherapeutic target. We previously reported the safety of and immunological and clinical responses to a GPC3-derived peptide vaccine in a phase I clinical trial of patients with advanced hepatocellular carcinoma (HCC). Although the efficacy of the GPC3-derived peptide vaccine against HCC patients was evaluated, other GPC3-positive cancer patients have not yet been investigated. Therefore, we conducted a phase II trial to evaluate the clinical outcome of ovarian CCC patients treated with a GPC3-derived peptide vaccine. The GPC3 peptide was administered at a dose of 3 mg per body. Patients received an intradermal injection of the GPC3 peptide emulsified with incomplete Freund’s adjuvant. Vaccinations were performed biweekly from the first until the 6th injection and were then repeated at 6-week intervals after the 7th injection. Treatment continued until disease progression. We herein present two patients with chemotherapy-refractory ovarian CCC who achieved a significant clinical response in an ongoing trial of a GPC3 peptide vaccine. Case 1, a 42-year-old patient with advanced recurrent ovarian CCC with liver and retroperitoneal lymph node metastases, received the HLA-A24-restricted GPC3 peptide vaccine. Contrast-enhanced CT at week 10 revealed a partial response (PR) using RECIST criteria. Case 2 was a 67-year-old female with multiple lymph node metastases. She was injected with the HLA-A2-restricted GPC3 peptide vaccine. According to RECIST, PR was achieved at week 37. The stabilization of their diseases over one year provided us with the first clinical evidence to demonstrate that GPC3 peptide-based immunotherapy may significantly prolong the overall survival of patients with refractory ovarian CCC." @default.
• W2028763729 created "2016-06-24" @default.
• W2028763729 creator A5021170427 @default.
• W2028763729 creator A5058903905 @default.
• W2028763729 creator A5067576408 @default.
• W2028763729 creator A5076332969 @default.
• W2028763729 date "2013-11-21" @default.
• W2028763729 modified "2023-09-26" @default.
• W2028763729 title "Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy" @default.
• W2028763729 cites W1979879868 @default.
• W2028763729 cites W1984029678 @default.
• W2028763729 cites W2001877789 @default.
• W2028763729 cites W2009572702 @default.
• W2028763729 cites W2017675802 @default.
• W2028763729 cites W2050825468 @default.
• W2028763729 cites W2050979643 @default.
• W2028763729 cites W2055159339 @default.
• W2028763729 cites W2077704625 @default.
• W2028763729 cites W2109653150 @default.
• W2028763729 cites W2126014520 @default.
• W2028763729 cites W2132286877 @default.
• W2028763729 cites W2158925892 @default.
• W2028763729 cites W2170369650 @default.
• W2028763729 cites W2322311093 @default.
• W2028763729 cites W2322558359 @default.
• W2028763729 doi "https://doi.org/10.4161/hv.27217" @default.
• W2028763729 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4185885" @default.
• W2028763729 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24252799" @default.
• W2028763729 hasPublicationYear "2013" @default.
• W2028763729 type Work @default.
• W2028763729 sameAs 2028763729 @default.
• W2028763729 citedByCount "27" @default.
• W2028763729 countsByYear W20287637292014 @default.
• W2028763729 countsByYear W20287637292015 @default.
• W2028763729 countsByYear W20287637292016 @default.
• W2028763729 countsByYear W20287637292018 @default.
• W2028763729 countsByYear W20287637292019 @default.
• W2028763729 countsByYear W20287637292020 @default.
• W2028763729 countsByYear W20287637292021 @default.
• W2028763729 countsByYear W20287637292022 @default.
• W2028763729 crossrefType "journal-article" @default.
• W2028763729 hasAuthorship W2028763729A5021170427 @default.
• W2028763729 hasAuthorship W2028763729A5058903905 @default.
• W2028763729 hasAuthorship W2028763729A5067576408 @default.
• W2028763729 hasAuthorship W2028763729A5076332969 @default.
• W2028763729 hasBestOaLocation W20287637291 @default.
• W2028763729 hasConcept C121608353 @default.
• W2028763729 hasConcept C126322002 @default.
• W2028763729 hasConcept C143998085 @default.
• W2028763729 hasConcept C147483822 @default.
• W2028763729 hasConcept C195616568 @default.
• W2028763729 hasConcept C203014093 @default.
• W2028763729 hasConcept C2776789287 @default.
• W2028763729 hasConcept C2777701055 @default.
• W2028763729 hasConcept C2777863537 @default.
• W2028763729 hasConcept C2778019345 @default.
• W2028763729 hasConcept C2779742787 @default.
• W2028763729 hasConcept C2780427987 @default.
• W2028763729 hasConcept C2780849966 @default.
• W2028763729 hasConcept C535046627 @default.
• W2028763729 hasConcept C71924100 @default.
• W2028763729 hasConcept C90924648 @default.
• W2028763729 hasConceptScore W2028763729C121608353 @default.
• W2028763729 hasConceptScore W2028763729C126322002 @default.
• W2028763729 hasConceptScore W2028763729C143998085 @default.
• W2028763729 hasConceptScore W2028763729C147483822 @default.
• W2028763729 hasConceptScore W2028763729C195616568 @default.
• W2028763729 hasConceptScore W2028763729C203014093 @default.
• W2028763729 hasConceptScore W2028763729C2776789287 @default.
• W2028763729 hasConceptScore W2028763729C2777701055 @default.
• W2028763729 hasConceptScore W2028763729C2777863537 @default.
• W2028763729 hasConceptScore W2028763729C2778019345 @default.
• W2028763729 hasConceptScore W2028763729C2779742787 @default.
• W2028763729 hasConceptScore W2028763729C2780427987 @default.
• W2028763729 hasConceptScore W2028763729C2780849966 @default.
• W2028763729 hasConceptScore W2028763729C535046627 @default.
• W2028763729 hasConceptScore W2028763729C71924100 @default.
• W2028763729 hasConceptScore W2028763729C90924648 @default.
• W2028763729 hasIssue "2" @default.
• W2028763729 hasLocation W20287637291 @default.
• W2028763729 hasLocation W20287637292 @default.
• W2028763729 hasLocation W20287637293 @default.
• W2028763729 hasLocation W20287637294 @default.
• W2028763729 hasOpenAccess W2028763729 @default.
• W2028763729 hasPrimaryLocation W20287637291 @default.
• W2028763729 hasRelatedWork W1973553003 @default.
• W2028763729 hasRelatedWork W1986962886 @default.
• W2028763729 hasRelatedWork W2002432836 @default.
• W2028763729 hasRelatedWork W2050825468 @default.
• W2028763729 hasRelatedWork W2176908693 @default.
• W2028763729 hasRelatedWork W2410536870 @default.
• W2028763729 hasRelatedWork W2569732664 @default.
• W2028763729 hasRelatedWork W3028490328 @default.
• W2028763729 hasRelatedWork W3095032159 @default.
• W2028763729 hasRelatedWork W4250535920 @default.
• W2028763729 hasVolume "10" @default.
• W2028763729 isParatext "false" @default.
• W2028763729 isRetracted "false" @default.

• next